可那木单抗
化合物
可那木单抗（INN：Conatumumab；开发代号：AMG-655），或译可那妥木单抗，是一种用于治疗癌症的单克隆抗体。它是一种全人源单克隆激动剂抗体，针对人肿瘤坏死因子相关凋亡诱导配体（TRAIL）受体2（TR-2，死亡受体5）的胞外结构域，具有潜在的抗肿瘤活性。[1][2]可那木单抗模仿天然TRAIL的活性，结合并激活TR-2，从而激活胱天蛋白酶级联反应并诱导肿瘤细胞凋亡。TR-2由多种实体瘤和造血来源的癌症表达。[3][4]
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目标 | TRAIL-R2 (CD262) |
| 临床资料 | |
| 其他名称 | 可那妥木单抗、抗TRAIL受体2单克隆抗体、AMG-655 |
| ATC码 |
|
| 识别信息 | |
| CAS号 | 896731-82-1  |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6466H10006N1730O2024S40 |
| 摩尔质量 | 145,645.66 g·mol−1 |
参考资料
编辑- ^ Rosevear HM, Lightfoot AJ, Griffith TS. Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer. Current Opinion in Investigational Drugs (London, England). June 2010, 11 (6): 688–98. PMID 20496264.
- ^ Bajaj M, Heath EI. Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults. Expert Opinion on Biological Therapy. November 2011, 11 (11): 1519–24. PMID 21877997. S2CID 28520935. doi:10.1517/14712598.2011.610788.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council – Conatumumab （页面存档备份，存于互联网档案馆）, American Medical Association.
- ^ National Cancer Institute: Definition of conatumomab. [2024-01-22]. （原始内容存档于2009-05-09）.